Literature DB >> 35905482

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

Andrea Kokorovic1, Alan I So2, Hosam Serag2, Christopher French3, Robert J Hamilton4, Jason P Izard5, Jasmir G Nayak6, Frédéric Pouliot7, Fred Saad1, Bobby Shayegan8, Armen Aprikian9, Ricardo A Rendon10.   

Abstract

Entities:  

Year:  2022        PMID： 35905482      PMCID： PMC9343157          DOI： 10.5489/cuaj.8054

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  136 in total

1.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Authors:  Paul L Nguyen; Youjin Je; Fabio A B Schutz; Karen E Hoffman; Jim C Hu; Arti Parekh; Joshua A Beckman; Toni K Choueiri
Journal:  JAMA       Date:  2011-12-07       Impact factor: 56.272

Review 2.  Cognitive changes associated with ADT: a review of the literature.

Authors:  Rhoda J Jamadar; Mary J Winters; Pauline M Maki
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

3.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

4.  2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

Authors:  Fred Saad; Armen Aprikian; Antonio Finelli; Neil E Fleshner; Martin Gleave; Anil Kapoor; Tamim Niazi; Scott A North; Frederic Pouliot; Ricardo A Rendon; Bobby Shayegan; Srikala S Sridhar; Alan So; Nawaid Usmani; Eric Vigneault; Kim N Chi
Journal:  Can Urol Assoc J       Date:  2021-02       Impact factor: 1.862

5.  Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life.

Authors:  Stacy Elliott; David M Latini; Lauren M Walker; Richard Wassersug; John W Robinson
Journal:  J Sex Med       Date:  2010-09       Impact factor: 3.802

Review 6.  Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials.

Authors:  Freerk T Baumann; Eva M Zopf; Wilhelm Bloch
Journal:  Support Care Cancer       Date:  2011-10-12       Impact factor: 3.603

7.  Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts.

Authors:  W D Leslie; C Berger; L Langsetmo; L M Lix; J D Adachi; D A Hanley; G Ioannidis; R G Josse; C S Kovacs; T Towheed; S Kaiser; W P Olszynski; J C Prior; S Jamal; N Kreiger; D Goltzman
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

8.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Authors:  Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

9.  Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.

Authors:  Kristin L Campbell; Kerri M Winters-Stone; Joachim Wiskemann; Anne M May; Anna L Schwartz; Kerry S Courneya; David S Zucker; Charles E Matthews; Jennifer A Ligibel; Lynn H Gerber; G Stephen Morris; Alpa V Patel; Trisha F Hue; Frank M Perna; Kathryn H Schmitz
Journal:  Med Sci Sports Exerc       Date:  2019-11       Impact factor: 5.411

10.  Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.

Authors:  David P Smith; Madeleine T King; Sam Egger; Martin P Berry; Phillip D Stricker; Paul Cozzi; Jeanette Ward; Dianne L O'Connell; Bruce K Armstrong
Journal:  BMJ       Date:  2009-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.